In vivo screening of interferon gamma (IFN-γ)-polarised M1 CAR-iMACS in an ovarian cancer model showed that CAR-iMACS has a rapid expansion rate and can persist for more than 20 days in a system with significant anticancer activity (53). Here, IFNG is linked to ovarian cancer.